Drugs / AAA602
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06881823 Comparator | Jun 2026 → Mar 2030 | prostate cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAA602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06881823 ↗ |
| Route | Intravenous | “AAA602 will be administered as a single intravenous dose.” NCT06881823 ↗ |